Tina deVries
2019
In 2019, Tina deVries earned a total compensation of $1.5M as EVP, Research & Development at RVL Pharmaceuticals plc, a 174% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $285,360 |
|---|---|
| Salary | $414,539 |
| Stock Awards | $799,998 |
| Other | $11,200 |
| Total | $1,511,097 |
deVries received $800K in stock awards, accounting for 53% of the total pay in 2019.
deVries also received $285.4K in non-equity incentive plan, $414.5K in salary and $11.2K in other compensation.
Rankings
In 2019, Tina deVries' compensation ranked 7,283rd out of 13,971 executives tracked by ExecPay. In other words, deVries earned more than 47.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,283 out of 13,971 | 48th |
Division Manufacturing | 2,805 out of 5,701 | 51st |
Major group Chemicals And Allied Products | 1,045 out of 2,200 | 53rd |
Industry group Drugs | 889 out of 1,886 | 53rd |
Industry Pharmaceutical Preparations | 659 out of 1,398 | 53rd |
Source: SEC filing on April 20, 2020.
deVries' colleagues
We found three more compensation records of executives who worked with Tina deVries at RVL Pharmaceuticals plc in 2019.
News
RVL Pharmaceuticals plc Former EVP, Research & Development Tina deVries' 2022 pay slips 19% to $561K
April 24, 2023
RVL Pharmaceuticals plc CEO Brian Markison's 2021 pay falls 63% to $1.4M
April 25, 2022
RVL Pharmaceuticals plc CEO Brian Markison's 2020 pay slips 12% to $3.8M
April 26, 2021
RVL Pharmaceuticals plc CEO Brian Markison's 2019 pay jumps 291% to $4.3M
April 20, 2020
RVL Pharmaceuticals plc CEO Brian Markison's 2018 pay slips 10% to $1.1M
April 26, 2019